Business
Alzamend Neuro is a clinical-stage biopharma company developing products for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
Alzamend Neuro had no revenue tagged, but FY2025 net loss narrowed to $4.5M and equity turned positive.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage neuropsychiatric pipelineNote
- Revenue — No revenue taggedNote
- Profitability — Net loss narrowed to $4.5MNote
- Cash — Cash from ops negative $6.6MNote
- Equity — Equity improved to $4.0MOK
- Insiders — 1 buy / 25 sellsWatch
- Accounting — No forensic screen in bundleNote
Leadership changes
From Alzamend Neuro, Inc.'s own filings, the day they're filed.
- Milton C. Ault III · appointmenteff. 2024-01-04
Latest filings
- 8-K · Company announcement2026-08-03
- 10-K · Annual report2026-07-22
- 8-K · Company announcement2026-07-21
- 8-K · Company announcement2026-04-17
- 8-K · Company announcement2026-03-20
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Alzamend Neuro, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.